Association of polymorphisms in cyclooxygenase (COX)-2 with coronary and carotid calcium in the Diabetes Heart Study

Atherosclerosis

Volumn 203, Issue 2, 2009, Pages 459-465

  Rudock, Megan E ^a   Liu, Yongmei ^a   Ziegler, Julie T ^a   Allen, Stewart G ^a   Lehtinen, Allison B ^a   Freedman, Barry I ^a   Carr, J Jeffrey ^a   Langefeld, Carl D ^a   Bowden, Donald W ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Cyclooxygenase; Inflammation; Polymorphisms; Type 2 diabetes mellitus; Vascular calcification

Indexed keywords

ANTILIPEMIC AGENT; CALCIUM; CYCLOOXYGENASE 2; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGE DISTRIBUTION; ALLELE; AORTA; ARTERY CALCIFICATION; ARTICLE; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CAUCASIAN; CORONARY ARTERY; FAMILY; FEMALE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEX DIFFERENCE; SIBLING; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

AGED; ALLELES; CALCIUM; CAROTID ARTERIES; CORONARY VESSELS; CYCLOOXYGENASE 2; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FAMILY HEALTH; FEMALE; GENOMICS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; POLYMORPHISM, GENETIC;

EID: 62649173099     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.07.018     Document Type: Article

References (35)

1. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-171
2. Belton O., Byrne D., Kearney D., Leahy A., and Fitzgerald D.J. Cyclooxygenase-1 and 2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102 (2000) 840-845
3. Davidge S.T. Prostaglandin H synthase and vascular function. Circ Res 89 (2001) 650-660
4. Grosser T., Fries S., and FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116 (2006) 4-15
5. Antman E.M., DeMets D., and Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 112 (2005) 759-770
6. Hla T., and Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 89 (1992) 7384-7388
7. Tazawa R., Xu X.M., Wu K.K., and Wang L.H. Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun 203 (1994) 190-199
8. Cipollone F., Fazia M., Iezzi A., et al. Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans. Arterioscler Thromb Vasc Biol 24 (2004) 1259-1265
9. 2-dependent plaque instability. Circulation 104 (2001) 921-927
10. Cipollone F., Toniato E., Martinotti S., et al. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 291 (2004) 2221-2228
11. Kohsaka S., Volcik K.A., Folsom A.R., et al. Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: The Atherosclerosis Risk in Communities Study. Atherosclerosis 96 2 (2007) 926-930
12. Lee C.R., North K.E., Bray M.S., et al. Cyclooxygenase polymorphisms risk of cardiovascular events: The Atherosclerosis Risk in Communities (ARIC) Study. Clin Pharmacol Ther 83 1 (2007) 50-62
13. Orbe J., Beloqui O., Rodriguez J.A., et al. Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors. Clin Chim Acta 368 (2006) 138-143
14. Konheim Y.L., and Wolford J.K. Association of a promoter variant in the inducible cyclooxygenase-2 gene (PTGS2) with type 2 diabetes mellitus in Pima Indians. Hum Genet 113 (2003) 377-381
15. Wagenknecht L.E., Bowden D.W., Carr J.J., Langefeld C.D., Freedman B.I., and Rich S.S. Familial aggregation of coronary artery calcium in families with type 2 diabetes. Diabetes 50 (2001) 861-866
16. Lange L.A., Bowden D.W., Langefeld C.D., et al. Heritability of carotid artery intima-medial thickness in type 2 diabetes. Stroke 33 (2002) 1876-1881
17. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
18. Carr J.J., Nelson J.C., Wong N.D., et al. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) Study. Radiology 234 (2005) 35-43
19. Wagenknecht L.E., Langefeld C.D., Freedman B.I., Carr J.J., and Bowden D.W. A comparison of risk factors for calcified atherosclerotic plaque in the coronary, carotid, and abdominal aortic arteries: The Diabetes Heart Study. Am J Epidemiol 166 3 (2007) 340-347
20. Detrano R.C., Anderson M., Nelson J., Wong N.D., Carr J.J., McNitt-Gray M., and Bild D.E. Coronary calcium measurements: effect of CT scanner type and calcium measure on rescan reproducibility-MESA study. Radiology 236 (2005) 477-484
21. Bensen J.T., Langefeld C.D., Hawkins G.A., et al. Nucleotide variation, haplotype structure, and association with end-stage renal disease of the human interleukin-1 gene cluster. Genomics 82 (2003) 194-217
22. Almasy L., and Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 62 (1998) 1198-1211
23. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 25 (2003) 115-121
24. A haplotype map of the human genome. Nature 2005;437:1299-1320.
25. de Bakker P.I., Yelensky R., Pe'er I., et al. Efficiency and power in genetic association studies. Nat Genet 37 (2005) 1217-1223
26. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
27. Gabriel S.B., Schaffner S.F., Nguyen H., et al. The structure of haplotype blocks in the human genome. Science 296 (2002) 2225-2229
28. Wang N., Akey J.M., Zhang K., Chakraborty R., and Jin L. Distribution of recombination crossovers and the origin of haplotype blocks: the interplay of population history, recombination, and mutation. Am J Hum Genet 71 (2002) 1227-1234
29. Szczeklik W., Sanak M., and Szczeklik A. Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol 114 (2004) 248-253
30. Shi J., Misso N.L., Duffy D.L., Thompson P.J., and Kedda M.A. A functional polymorphism in the promoter region of the cyclooxygenase-2 gene is not associated with asthma and atopy in an Australian population. Clin Exp Allergy 34 (2004) 1714-1718
31. Zhang X., Miao X., Tan W., et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 129 (2005) 565-576
32. Kang S., Kim Y.B., Kim M.H., et al. Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer. Cancer Lett 217 (2005) 11-16
33. Panguluri R.C., Long L.O., Chen W., et al. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 25 (2004) 961-966
34. Papafili A., Hill M.R., Brull D.J., et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 22 (2002) 1631-1636
35. Hegener H.H., Diehl K.A., Kurth T., et al. Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene C-reactive protein concentrations and risk of atherothrombosis: a nested case-control approach. J Thromb Haemost 4 (2006) 1718-1722